Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach to discuss the trials in combination therapy for Chronic Lymphocytic Leukemia and the phase 2 trial results with Obinutuzumab, Ibrutunib, & Venetoclax in conjunction.
Trials in Combination Therapy for CLL – Phase 2 Trial results with Obinutuzumab, Ibrutunib, & Venetoclax
